[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fek19lRF7SfVC8bBGcNKCyn21QJGlT3T4mVKkEfPMJZI":8,"$fwsUz-Z_GRzY85aEyCkgfeV8QWO0RlGLTZkOiKUhnxDk":55,"$fotH4lrDvTfJx0dqX41YQbVZ25rRntAS4Lb_b_Pm39QY":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},59871,870213,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//hk0nky0jW6hC6kA5kTPwGdSYQ068rXoE.png","俞宁娟","浙江大学医学院附属第二医院","肿瘤科","主治医师",34,0,"肝癌复发用药方案实用指南：靶向药物与免疫治疗的关键细节","","https://ystcdn.venuertc.com/venue/AI/4623326c-b415-4650-9716-c788a44138c8.jpg","\u003Cdiv class=\"liverdrug-guide-container\">\n  \u003Ch1 id=\"material_title\" class=\"liverdrug-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n    肝癌复发用药方案实用指南：靶向药物与免疫治疗的关键细节\n  \u003C/h1>\n  \u003Cdiv class=\"liverdrug-intro\">\n    \u003Cp>\n      说起靶向药物和免疫治疗，这是现代肿瘤药物领域的热门话题。对于有肝癌复发治疗需求的人来说，仑伐替尼、瑞戈非尼和替雷利珠单抗已经成为常见的选择。不过，这几类药品在使用上有不少讲究。今天我们就来系统梳理下它们在实际应用时必须关注的7个细节，帮助大家用得安全、放心。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 靶向药物与免疫治疗剂型介绍 -->\n  \u003Csection class=\"liverdrug-section\">\n    \u003Cdiv class=\"liverdrug-section-header liverdrug-bg-1\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 🧴 剂型和基本用药方式\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"liverdrug-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼：\u003C/strong>口服胶囊或片剂，规格常见为4mg和10mg，患者按医师建议每日一次吞服。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>瑞戈非尼：\u003C/strong>口服片剂，常见规格为40mg。需整片吞服，避免嚼碎或压碎。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>替雷利珠单抗：\u003C/strong>静脉输注制剂，需在医院进行，每次输注约30~60分钟，不建议自行操作。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"liverdrug-highlighted\">正确做法：\u003C/span>吃药按医嘱用固定的剂量和服药频率，绝不随意增减。部分药品如免疫制剂只能在医院进行。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 靶向药物作用机制简介 -->\n  \u003Csection class=\"liverdrug-section\">\n    \u003Cdiv class=\"liverdrug-section-header liverdrug-bg-2\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 🔬 药物作用机制简述\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"liverdrug-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼：\u003C/strong>通过抑制多种酪氨酸激酶受体，阻断肿瘤血管生长，减少新生血管供应，从而影响癌细胞存活。\u003Csup>[1]\u003C/sup>\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>瑞戈非尼：\u003C/strong>多靶点激酶抑制剂，针对肿瘤生长和血管生成多个信号通路发挥作用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>替雷利珠单抗：\u003C/strong>这种PD-1免疫检查点抑制剂通过激活自身免疫细胞，提高对白细胞抗性肿瘤的识别清除能力。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        这些药品的机制虽然不同，但都属于现代精准用药的代表。避开传统的广谱性毒副作用，实现更有针对性的干预。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 药物使用时机和方法 -->\n  \u003Csection class=\"liverdrug-section\">\n    \u003Cdiv class=\"liverdrug-section-header liverdrug-bg-3\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 ⏰ 服用时间与方法要求\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"liverdrug-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼：\u003C/strong>建议每天同一时间空腹或随餐服用均可，但需要用水整粒吞服，避免咀嚼。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>瑞戈非尼：\u003C/strong>务必在高脂餐后约2小时服药，可以减轻消化道不适反应。与食物同服会影响药效释放，不建议部分食物并用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>替雷利珠单抗：\u003C/strong>由专业医疗人员按疗程定期静脉输注，患者只需配合接受，不负责操作。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        若漏服一次，不要一次服下双倍剂量。发现漏服，按说明及时补服或直接跳过一次，以后按原计划用药。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 药物相互作用（重点） -->\n  \u003Csection class=\"liverdrug-section\">\n    \u003Cdiv class=\"liverdrug-section-header liverdrug-bg-4\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 🔄 常见药物相互作用\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"liverdrug-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼：\u003C/strong>禁止与强力CYP3A4抑制剂（如克拉霉素、酮康唑）同服。否则血药浓度可能升高，增加毒副作用风险。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>瑞戈非尼：\u003C/strong>避免与利福平、苯妥英钠等药物共用，否则会影响效果。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>替雷利珠单抗：\u003C/strong>不建议同时使用其他免疫抑制剂和糖皮质激素，以免干扰疗效。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"liverdrug-highlighted\">建议：\u003C/span>开始新药前主动报备所有正在服用的药物，包括保健品和中草药。若需调整，一定由医生指导完成。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 用药注意事项及特殊人群 -->\n  \u003Csection class=\"liverdrug-section\">\n    \u003Cdiv class=\"liverdrug-section-header liverdrug-bg-5\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 👩‍⚕️ 特殊人群用药须知\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"liverdrug-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>老年人：\u003C/strong>两种靶向药物因代谢能力变化，通常要适当调整剂量。首次用药最好用低剂量起步，严密监测可能的不良反应。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>肝肾功能不全：\u003C/strong>仑伐替尼与瑞戈非尼在肝肾功能下降时要谨慎。免疫制剂（如替雷利珠单抗）使用时尤其应关注副反应。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>孕妇及哺乳期妇女：\u003C/strong>说明书建议孕期、哺乳期尽量避免使用。如果必须服用，应有严密随访和风险评估。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        实际中有一位女性患者（60kg），多次接受仑伐替尼、瑞戈非尼及替雷利珠单抗的联合方案。疗程内无明显副作用，但每次调整药物均征得医生同意。这提醒特殊人群安全用药必须谨慎。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 不良反应及处理 -->\n  \u003Csection class=\"liverdrug-section\">\n    \u003Cdiv class=\"liverdrug-section-header liverdrug-bg-6\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 ⚠️ 常见不良反应与处理建议\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"liverdrug-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼：\u003C/strong>主要可能发生高血压、蛋白尿、疲劳等。如有新出现的持续高血压，应及时就医。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>瑞戈非尼：\u003C/strong>常见食欲变差、乏力和手足综合征（手脚发红疼痛）。轻微时对症处理，严重时暂停或调整剂量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>替雷利珠单抗：\u003C/strong>少部分患者会有免疫相关反应，如皮疹、发烫等。须由医院医生密切监控。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"liverdrug-highlighted\">正确做法：\u003C/span>监测血压、蛋白尿和肝肾功能指标。出现明显身体不适立即告知医生，不可自行调整用药方案。\n        \u003Cbr>数据显示，仑伐替尼相关严重不良反应发生率为10-20%（参考资料1）。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 储存方法和有效期 -->\n  \u003Csection class=\"liverdrug-section\">\n    \u003Cdiv class=\"liverdrug-section-header liverdrug-bg-7\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 🗄️ 储存要求和过期处理\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"liverdrug-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼和瑞戈非尼：\u003C/strong>须存放于阴凉干燥处，避免阳光直射。保持原包装，远离儿童。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>替雷利珠单抗：\u003C/strong>注射液需冷藏（2-8℃），用前取出静置回温，不可直接冷冻。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        超过有效期的药品务必按药品管理规定处理，不要随意丢弃或服用。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 漏服、过量用药应对策略 -->\n  \u003Csection class=\"liverdrug-section\">\n    \u003Cdiv class=\"liverdrug-section-header liverdrug-bg-8\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 ⛑️ 遇到漏服和过量怎么处理？\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"liverdrug-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>漏服：\u003C/strong>如忘记吃药，想起来时尽快补服，但如果快到下次服药时间，就直接略过这次，继续原计划。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>过量：\u003C/strong>如果不小心多服，应立即记录服药时间和剂量，并迅速联系医生或前往正规医疗机构。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        切忌自行加倍或停止用药，每次用药异常务必主动上报。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 用药小结与安全提醒 -->\n  \u003Csection class=\"liverdrug-section\">\n    \u003Cdiv class=\"liverdrug-section-header liverdrug-bg-9\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 📒 重点小结与安全提醒\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"liverdrug-section-content\">\n      \u003Cp>\n        靶向和免疫药物让现代治疗更为精准，但用药的细节绝不能忽视。首先，请遵循剂型、服药时间和剂量要求，其次务必警惕相互作用及不良反应。任何异样应及时就医；药品储存、过期处理切勿马虎。\n      \u003C/p>\n      \u003Cp>\n        合理用药的最后一道防线，就是自己对细节的把握。如果在实际用药过程中有疑惑，记得及时和医生、药师沟通。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 参考文献 -->\n  \u003Csection class=\"liverdrug-section\">\n    \u003Cdiv class=\"liverdrug-section-header liverdrug-bg-10\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">🔗 参考文献\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"liverdrug-section-content liverdrug-reference\">\n      \u003Col>\n        \u003Cli>\n          Kudo, M., Finn, R. S., Qin, S., et al. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.\u003Cem> The Lancet, 391\u003C/em>(10126), 1163-1173. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29433850/\" target=\"_blank\" rel=\"noopener\">https://pubmed.ncbi.nlm.nih.gov/29433850/\u003C/a>\n        \u003C/li>\n        \u003Cli>\n          Bruix, J., Qin, S., Merle, P., et al. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. \u003Cem>Lancet, 389\u003C/em>(10064), 56-66. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27932229/\" target=\"_blank\" rel=\"noopener\">https://pubmed.ncbi.nlm.nih.gov/27932229/\u003C/a>\n        \u003C/li>\n        \u003Cli>\n          Cui, J., Zhang, W., Li, W., et al. (2021). Safety, efficacy, and biomarker exploration in patients with advanced hepatocellular carcinoma treated with the anti–PD-1 antibody tislelizumab.\u003Cem> JAMA Oncology, 7\u003C/em>(6), 872-880. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33797541/\" target=\"_blank\" rel=\"noopener\">https://pubmed.ncbi.nlm.nih.gov/33797541/\u003C/a>\n        \u003C/li>\n      \u003C/ol>\n    \u003C/div>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.liverdrug-guide-container {\n  max-width: 900px;\n  margin: 48px auto;\n  padding: 40px 28px;\n  background: #faf9f5;\n  border-radius: 18px;\n  box-shadow: 0 6px 24px rgba(40,35,50,0.09);\n  font-family: \"Microsoft YaHei\",Arial,sans-serif;\n  color: #2b2a25;\n  font-size: 18px;\n  line-height: 1.74;\n}\n.liverdrug-title {\n  font-size: 2.6em;\n  font-weight: 700;\n  margin-bottom: 32px;\n  text-align: center;\n  background: linear-gradient(90deg,#a5c9d7,#fde8a5);\n  -webkit-background-clip: text;\n  -webkit-text-fill-color: transparent;\n  letter-spacing: 1px;\n}\n.liverdrug-intro {\n  margin: 0 0 34px 0;\n  padding-bottom: 12px;\n  font-size: 1.15em;\n  border-bottom: 2px solid #e1e6ea;\n}\n.liverdrug-section {\n  margin: 44px 0 0 0;\n}\n.liverdrug-section-header {\n  padding: 15px 0 13px 24px;\n  border-radius: 12px 12px 0 0;\n  font-size: 1.3em;\n  font-weight: 600;\n  letter-spacing: 1px;\n}\n.liverdrug-bg-1 {\n  background: linear-gradient(90deg,#ecf2fc 80%, #f5eab8);\n}\n.liverdrug-bg-2 {\n  background: linear-gradient(90deg,#e2ebf4 70%, #e9f5e5 110%);\n}\n.liverdrug-bg-3 {\n  background: linear-gradient(90deg,#e3eaf7 65%, #f7ebd5 115%);\n}\n.liverdrug-bg-4 {\n  background: linear-gradient(90deg,#e2eee9 77%,#e7dede 110%);\n}\n.liverdrug-bg-5 {\n  background: linear-gradient(87deg,#eef4f9 74%, #fff3e7 118%);\n}\n.liverdrug-bg-6 {\n  background: linear-gradient(90deg,#e9f0fa 55%, #ffe9c3 115%);\n}\n.liverdrug-bg-7 {\n  background: linear-gradient(90deg,#e0efe4 75%, #f8e7fb 110%);\n}\n.liverdrug-bg-8 {\n  background: linear-gradient(90deg,#f3e9ee 80%, #e1f2f4 110%);\n}\n.liverdrug-bg-9 {\n  background: linear-gradient(90deg,#edf3ea 75%, #fcf4e1 110%);\n}\n.liverdrug-bg-10 {\n  background: linear-gradient(90deg,#e8eaf3 95%, #f6efea 120%);\n}\n.liverdrug-section-content {\n  background: #f7f8fa;\n  padding: 23px 28px 20px 30px;\n  border-radius: 0 0 14px 14px;\n  border-bottom: 1.5px solid #f2f1ea;\n  border-right: 1px solid #f3e7d6;\n  border-left: 1px solid #e9e7ea;\n}\n.liverdrug-section-content ul {\n  margin: 0 0 12px 18px;\n  padding: 0;\n}\n.liverdrug-section-content ul li {\n  margin: 0 0 7px 0;\n  padding-left: 0.5em;\n  list-style: disc inside;\n}\n.liverdrug-highlighted {\n  color: #768cdf;\n  font-weight: 600;\n  background: #eaefff;\n  border-radius: 5px;\n  padding: 0 9px;\n  margin-right: 1em;\n}\n.liverdrug-reference {\n  font-size: 0.96em;\n  color: #656767;\n  margin-bottom: -6px;\n}\n.liverdrug-reference em {\n  font-style: italic;\n  color: #9a6d28;\n}\n.liverdrug-section-content a {\n  color: #3e6db1;\n  text-decoration: underline dashed;\n  word-break: break-all;\n}\n@media (max-width:600px) {\n  .liverdrug-guide-container {\n    padding: 14px 1em;\n    font-size: 15px;\n  }\n  .liverdrug-title {\n    font-size: 1.5em;\n    padding-top: 1em;\n  }\n  .liverdrug-section-content {\n    padding: 15px 5px 12px 10px;\n  }\n  .liverdrug-section-header {\n    padding: 11px 0 8px 9px;\n    font-size: 1.02em;\n  }\n}\n\u003C/style>\n","\u003Cdiv class=\"liverdrug-guide-container\">\n  \u003Ch1 id=\"material_title\" class=\"liverdrug-title\" style=\"col",534,"2025-08-18 10:47:47","肝癌, 靶向药物, 免疫治疗, 仑伐替尼, 瑞戈非尼, 替雷利珠单抗, 用药细节, 不良反应","本指南系统梳理了肝癌复发患者常用靶向药物仑伐替尼、瑞戈非尼与免疫治疗替雷利珠单抗的使用细节，为患者提供安全、有效的用药参考。","2025-08-20 09:32:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]